Healthcare entity

Moderna

Company MRNA

Negative sentiment reaches 0% here, compared with 23% across the 1333-story beat baseline for the same window. Moderna is most often covered alongside FDA, which appears in 3 of these 11 stories. That works out to roughly 0.4 stories per week across a 209-day span. The busiest single day carried 2.

Last mentioned: 5d ago

RSS updates
Share

Entity pulse

Recent coverage · Moderna

↑
11 stories
6.6 avg impact
45% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 45 percentage points.

  • 45% positive
  • 55% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Moderna

Negative sentiment reaches 0% here, compared with 23% across the 1333-story beat baseline for the same window. Moderna is most often covered alongside FDA, which appears in 3 of these 11 stories. That works out to roughly 0.4 stories per week across a 209-day span. The busiest single day carried 2. They are better corroborated than the beat average, carrying 3.9 original sources each against 3.4 for the same window. The 6.6 average consequence score is above the beat benchmark of 5.9 in the same window. Coverage clusters in market-trends, which accounts for 6 of those 11, with the remainder spread across 1 other category. We currently track 11 Healthcare stories that mention Moderna, published between February 19, 2026 and September 15, 2026.

Stories tracked
11
Per week
0.4
Negative
0%
Sources per story
3.9

Computed from the 11 stories linked to this entity, with beat comparisons drawn from all 1333 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Moderna. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Updated vaccines available

    Updated COVID-19 and flu vaccines become available in the Bay Area.

  2. FDA final decision deadline

    The agency must decide whether to approve the first mRNA-based influenza vaccine, with major implications for the platform’s future.

  3. Bay Area positivity hits 9%

    State data show positive COVID-19 tests at moderate levels, slightly more than 9%.

  4. Advisory panel recommends approval

    The FDA’s Vaccines and Related Biological Products Advisory Committee votes to recommend the mRNA flu shot for licensure.

  5. Regulatory U-Turn

    The FDA officially agrees to consider the application after resolving the internal and public dispute.

  6. Public Dispute

    Reports emerge that career FDA scientists were overruled, leading to a public standoff between Moderna and the agency.

  7. Initial Rejection

    Trump administration vaccine chief refuses to review Moderna's mRNA flu shot application.

  8. FDA refuses to review Moderna’s mRNA flu vaccine

    FDA sends a refusal-to-file letter, stunning Moderna executives. Moderna had prior indications that a review would proceed.

  9. FDA reverses decision after industry backlash

    About a week later, FDA agrees to review the application after Moderna commits to a confirmatory post-market study, following public outcry and pressure.

  10. Major SARS-CoV-2 variation emerges

    A major viral variation emerges and is later named XFG or Stratus.

  11. Trump administration relaxes COVID-19 vaccine recommendations

    Federal recommendations are relaxed, creating widespread confusion in the Bay Area.

Stories mentioning Moderna 11

Market Trends Strongly positive

Moderna's 460% Surge Meets Phase 3 mRNA Cancer Vaccine Breakthrough

Moderna's personalized cancer vaccine intismeran autogene significantly improved recurrence-free survival in phase 3 melanoma, validating mRNA beyond infectious disease. For healthcare leaders, the coming approval pathway raises operational questions about patient-specific manufacturing, oncology workflow integration, and cost. The milestone also realigns Moderna's portfolio as Spikevax revenue normalizes.

2 sources

Source: Prosper Junior Bakiny, The Motley Fool (us) · Prosper Junior Bakiny (us)

Health Policy Neutral

Federal Court Halts RFK Jr.’s Vaccine Policy Shift Amid Public Health Concerns

A federal judge has issued a temporary injunction against the vaccine policy agenda proposed by Robert F. Kennedy Jr., citing potential risks to public health infrastructure. While the ruling provides a reprieve for existing immunization standards, experts warn that the ongoing legal and political battle could further erode public confidence in scientific institutions.

6 sources
Market Trends Positive

Moderna and SaaS Infrastructure Lead Broad Health-Tech Market Rally

A significant market rally on March 4, 2026, saw shares of Moderna, Wix, and Cloudflare surge as investors prioritized biotech innovation and the digital infrastructure powering modern healthcare delivery. These gains reflect a growing convergence between clinical breakthroughs and the secure, scalable platforms required to manage patient engagement at scale.

5 sources

Source: markets.financialcontent.com · markets.financialcontent.com

Moderna is linked from 11 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.